Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Capmatinib
Biological: Pembrolizumab

First Posted Date: 2019-10-25

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 76

Registration Number: NCT04139317

Locations: 🇹🇭
Novartis Investigative Site, Bangkok, Thailand

Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: CFZ533
Other: Placebo

First Posted Date: 2019-10-16

Last Posted Date: 2024-07-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT04129528

Locations: 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom

A Study of WVT078 in Patients With Multiple Myeloma (MM)

Phase 1

Terminated

Conditions: Multiple Myeloma (MM)

Interventions: Biological: WVT078
Drug: WHG626

First Posted Date: 2019-10-10

Last Posted Date: 2025-01-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT04123418

Locations: 🇺🇸
Emory University School of Medicine-Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University Of Wisconsin, Madison, Wisconsin, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 1 locations

Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab

Phase 3

Withdrawn

Conditions: Migraine

Interventions: Drug: erenumab 70mg/mL

First Posted Date: 2019-10-03

Last Posted Date: 2020-06-01

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04114630

Locations: 🇪🇸
Novartis Investigatice Site, Madrid, Spain
🇪🇸
Novartis Investigational Site, Valencia, Comunidad Valenciana, Spain
🇪🇸
Novartis Investigative Site, Madrid, Spain

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

Phase 2

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: LOU064

First Posted Date: 2019-09-30

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 229

Registration Number: NCT04109313

Locations: 🇬🇧
Novartis Investigative Site, Plymouth, United Kingdom

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Phase 1

Completed

Conditions: Myelofibrosis

Interventions: Drug: Ruxolitinib
Drug: Crizanlizumab
Drug: Sabatolimab
Drug: Siremadlin
Drug: NIS793
Drug: Rineterkib

First Posted Date: 2019-09-20

Last Posted Date: 2024-12-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT04097821

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA

Phase 2

Active, not recruiting

Conditions: Osteoarthritis (OA)

Interventions: Drug: LRX712
Drug: Placebo

First Posted Date: 2019-09-20

Last Posted Date: 2024-12-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT04097379

Locations: 🇳🇱
Novartis Investigative Site, Leiden, Netherlands

Study of Out of Specification for Tisagenlecleucel

Phase 3

Recruiting

Conditions: B-cell Acute Lymphoblastic Leukemia
Diffuse Large B-cell Lymphoma

Interventions: Biological: CTL019

First Posted Date: 2019-09-18

Last Posted Date: 2024-10-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT04094311

Locations: 🇯🇵
Novartis Investigative Site, Wakayama, Japan

Managed Access Program (MAP) to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

Conditions: PIK3CA-Related Overgrowth Spectrum (PROS)

First Posted Date: 2019-09-11

Last Posted Date: 2024-10-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04085653

Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study

Phase 4

Completed

Conditions: Migraine Headache
Migraine
Migraine Disorders

Interventions: Biological: Erenumab

First Posted Date: 2019-09-10

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 701

Registration Number: NCT04084314

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy